Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Werewolf Therapeutics, Inc. (NASDAQ:HOWL) received an average rating of "Buy" from five brokerages, with a consensus twelve-month price target of $8.00.
• Recently, JMP Securities reduced their price target for the stock from $4.00 to $3.00, while Citigroup and Bank of America maintained buy ratings with price targets of $9.00 and $8.00 respectively.
• The company's latest earnings report showed an EPS of ($0.40), surpassing the projection of ($0.50) by $0.10.

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) have earned a consensus rating of "Buy" from the five ratings firms that are covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.00.

A number of equities research analysts recently commented on the company. Citigroup reissued a "buy" rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Bank of America cut their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, August 25th. Finally, JMP Securities dropped their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a report on Thursday, August 21st.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. D. E. Shaw & Co. Inc. bought a new position in Werewolf Therapeutics in the 4th quarter worth about $26,000. Quadrature Capital Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth $28,000. Vontobel Holding Ltd. acquired a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at about $34,000. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter worth about $48,000. Finally, Nuveen LLC acquired a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $71,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Stock Performance

HOWL traded up $0.27 during trading hours on Friday, reaching $2.11. The company's stock had a trading volume of 2,240,391 shares, compared to its average volume of 363,897. Werewolf Therapeutics has a 52 week low of $0.60 and a 52 week high of $4.18. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.30 and a current ratio of 5.30. The firm has a market cap of $96.63 million, a PE ratio of -1.27 and a beta of 0.64. The company's 50-day moving average is $1.34 and its 200-day moving average is $1.15.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.10. On average, equities analysts forecast that Werewolf Therapeutics will post -1.56 EPS for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.